wire - news in brief
« BACK
Health - Pharmacology - 16.06.2021 
How do immune cells get activated?
By studying the structure of cellular receptors and of the molecules that activate them, scientists at the Universities of Geneva and Basel are deciphering the details of immune cell activation. Chemokine receptors, located at the surface of many immune cells, play an important role in their function.
Pharmacology - Health - 16.06.2021
Pharmacology - Health - 11.06.2021
Health - Pharmacology - 11.06.2021
Pharmacology - Health - 11.06.2021
Pharmacology - Health - 07.06.2021
Pharmacology - Health - 07.06.2021
Pharmacology - Health - 06.06.2021
Pharmacology - Health - 04.06.2021
Pharmacology - Health - 04.06.2021
Pharmacology - Health - 04.06.2021
Pharmacology - Health - 03.06.2021
Pharmacology - Health - 03.06.2021
Pharmacology - Health - 02.06.2021
Pharmacology - Health - 02.06.2021
Pharmacology - Health - 02.06.2021
Health - Pharmacology - 01.06.2021 
The simulated patient
Digital twins enable customized medical therapies. researchers have now modeled several hundred such avatars based on real people and treated them experimentally.
Pharmacology - Health - 01.06.2021
Pharmacology - Health - 28.05.2021
Pharmacology - Health - 27.05.2021
Pharmacology - Health - 25.05.2021
Pharmacology - Health - 20.05.2021
Pharmacology - Health - 19.05.2021
Pharmacology - Economics / Business - 18.05.2021
Pharmacology - Health - 18.05.2021
Pharmacology - Health - 17.05.2021
Pharmacology - Health - 05.05.2021
Pharmacology - Health - 03.05.2021
Pharmacology - Health - 01.05.2021
Pharmacology - Health - 28.04.2021
Pharmacology - Health - 27.04.2021
Pharmacology - Health - 27.04.2021
Pharmacology - 23.04.2021
Pharmacology - Health - 23.04.2021
Pharmacology - Health - 22.04.2021
Pharmacology - Health - 16.04.2021
Health - Pharmacology - 15.04.2021
Pharmacology - Health - 15.04.2021
Health - Pharmacology - 31.03.2021
Health - Pharmacology - 30.03.2021
Health - Pharmacology - 30.03.2021
Pharmacology - Health - 30.03.2021
Health - Pharmacology - 25.03.2021
Pharmacology - Health - 24.03.2021 
Clinical Trial of Multi Drug-Resistant TB Treatment Ends Enrolment Early, Offering Hope for TB Patients
A trial aiming to find a better treatment for multidrug-resistant tuberculosis (MDR-TB) has stopped enrolling patients early after its independent data safety and monitoring board indicated that the regimen being studied is superior to current care, and that more patient data was extremely unlikely to change the trial's outcome.
Pharmacology - Health - 23.03.2021
Pharmacology - 23.03.2021
Health - Pharmacology - 18.03.2021 
Learning from the dead to help the living
The lungs are the primary, but not the only target of Covid-19. Early in the pandemic, Basel researchers were among the first to venture to perform autopsies on deceased Covid-19 patients, making important contributions to our understanding of the new infectious disease. Professor Alexandar Tzankov of the University of Basel is leading a research project highlighting the effects of the virus on the body's tissues and organs.
Pharmacology - Health - 15.03.2021
Pharmacology - Health - 11.03.2021
Health - Pharmacology - 11.03.2021
Pharmacology
Results 1 - 50 of 1600.
By studying the structure of cellular receptors and of the molecules that activate them, scientists at the Universities of Geneva and Basel are deciphering the details of immune cell activation. Chemokine receptors, located at the surface of many immune cells, play an important role in their function.
Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intraand extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal noctu
First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intraand extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal noctu
Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Four-year follow-up analysis from the phase III CLL14 study showed progression-free survival rate of 74.0% in previously untreated patients with chronic lymphocytic leukaemia (CLL) three years
Four-year follow-up analysis from the phase III CLL14 study showed progression-free survival rate of 74.0% in previously untreated patients with chronic lymphocytic leukaemia (CLL) three years
Novartis announces new interim analysis Phase II data for iptacopan in rare kidney disease C3 glomerulopathy (C3G)
Data shows investigational iptacopan improved estimated glomerular filtration rate (eGFR) slope and stabilized kidney function in patients with C3G 1 ; Phase III clinical trial to start in 2021 Resul
Data shows investigational iptacopan improved estimated glomerular filtration rate (eGFR) slope and stabilized kidney function in patients with C3G 1 ; Phase III clinical trial to start in 2021 Resul
Approval for New Alzheimer’s Drug Developed at UZH
The active ingredient aducanumab, which was discovered at the University of Zurich, has been approved for use in the United States as a treatment for Alzheimer's disease.
The active ingredient aducanumab, which was discovered at the University of Zurich, has been approved for use in the United States as a treatment for Alzheimer's disease.
Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduc tion of proteinuria 1 - a key risk predictor in kidney disease progressi
Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduc tion of proteinuria 1 - a key risk predictor in kidney disease progressi
Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma
Data for investigational CD20xCD3 bispecific antibodies and new combination regimens with Polivy showed enhanced clinical benefits for people with non-Hodgkin lymphoma in early studies Basel, 4 June
Data for investigational CD20xCD3 bispecific antibodies and new combination regimens with Polivy showed enhanced clinical benefits for people with non-Hodgkin lymphoma in early studies Basel, 4 June
Novartis announces Tabrecta first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC
Tabrecta (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data 1,2
Tabrecta (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data 1,2
Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera
At final analysis, study showed clinically relevant improvement in median overall survival with a difference of 11.7 months between arms (Hazard ratio (HR): 0.84 with 95% CI: (0.
At final analysis, study showed clinically relevant improvement in median overall survival with a difference of 11.7 months between arms (Hazard ratio (HR): 0.84 with 95% CI: (0.
Novartis Kisqali reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
MONALEESA-3 median overall survival (OS) results of 53.7 months underscore that Kisqali offers more life to postmenopausal women with HR+/HER2- metastatic breast cancer (MBC) in addition to th
MONALEESA-3 median overall survival (OS) results of 53.7 months underscore that Kisqali offers more life to postmenopausal women with HR+/HER2- metastatic breast cancer (MBC) in addition to th
Digital twins enable customized medical therapies. researchers have now modeled several hundred such avatars based on real people and treated them experimentally.
Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo 1 The sa
Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo 1 The sa
Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
Sandoz to begin enrolling patients with neovascular age-related macular degeneration in MYLIGHT Phase lll confirmatory efficacy and safety study 1 Neovascular age-related macular degeneration account
Sandoz to begin enrolling patients with neovascular age-related macular degeneration in MYLIGHT Phase lll confirmatory efficacy and safety study 1 Neovascular age-related macular degeneration account
ANTICOV: Largest Clinical Trial in Africa to Test New Drug Combination
The need for effective COVID-19 treatments remains particularly acute, especially in sub-Saharan Africa where access to vaccines is still extremely limited.
The need for effective COVID-19 treatments remains particularly acute, especially in sub-Saharan Africa where access to vaccines is still extremely limited.
Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging
The Elecsys EBV panel accurately identifies the EBV infection stage from a single blood sample, which means less confirmatory testing and, potentially, faster diagnosis for patients Clear and quick d
The Elecsys EBV panel accurately identifies the EBV infection stage from a single blood sample, which means less confirmatory testing and, potentially, faster diagnosis for patients Clear and quick d
A trial aiming to find a better treatment for multidrug-resistant tuberculosis (MDR-TB) has stopped enrolling patients early after its independent data safety and monitoring board indicated that the regimen being studied is superior to current care, and that more patient data was extremely unlikely to change the trial's outcome.
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive
Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive
The lungs are the primary, but not the only target of Covid-19. Early in the pandemic, Basel researchers were among the first to venture to perform autopsies on deceased Covid-19 patients, making important contributions to our understanding of the new infectious disease. Professor Alexandar Tzankov of the University of Basel is leading a research project highlighting the effects of the virus on the body's tissues and organs.
New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment
Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious, tr
Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious, tr
